Xilio Therapeutics Doses First Participant In Its Phase 1/2 Clinical Study Of XTX501 To Treat Metastatic Non-Small Cell Lung Cancer
Benzinga Newsdesk 3 weeks ago
NewsBiotechGeneral
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that the first patient has been
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in its Phase 1/2 clinical trial evaluating XTX501, a PD-1/masked IL-2 (alpha-optimized) bispecific antibody fusion protein, in patients with metastatic non-small cell lung cancer (NSCLC) who have previously received anti-PD(L)-1 therapy. Xilio also plans to present a trial-in-progress poster for XTX501 at the upcoming SITC Annual Meeting, highlighting the design of the Phase 1/2 clinical trial.
